AU
UK
CA
NZ
IND
US
Genmab A/S (NASDAQ:GMAB) has received a major regulatory milestone with the U.S.Food and Drug Administrationgranting approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide, collectively known as EPKINLY + R2, for adults with relapsed or refractory follicular lymphoma. This approval introduces the first-ever …
Olema Pharmaceuticals (NASDAQ:OLMA) gained significant market attention after Roche Holding AG (OTC:RHHBY) unveiled promising findings from its phase 3 lidERA trial evaluating giredestrant, an investigational oral selective estrogen receptor degrader, in patients with early-stage ER+/HER2- breast cancer. The large-scale study included more than 4,100 …
Vanda Pharmaceuticals Inc. (Nasdaq:VNDA) announced encouraging topline results from its randomized, double-blind, placebo-controlled study evaluating tradipitant for preventing nausea and vomiting triggered by GLP-1 receptor agonist therapy. The study examined adults who were overweight or obese and had no prior GLP-1 agonist exposure.Participants were …
Incyte(NASDAQ:INCY) has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval ofMinjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma after at least one …
Predictive Oncology launched a new digital asset treasury strategy centered on the ATH token.
Eledon Pharmaceuticals (NASDAQ:ELDN) released its third quarter 2025 update, highlighting significant clinical, regulatory, and financial developments. Central to the announcement were the encouraging results from the Phase 2 BESTOW trial, which evaluated tegoprubart as a potential alternative to traditional immunosuppressive therapies in kidney transplantation. …
Trevi Therapeutics (NASDAQ:TRVI) has received a series of updates from research firms in recent days. D. Boral Capital reaffirmed its "buy" rating on the stock with a target price of $19.00, suggesting a potential upside from the stock's most recent close. This aligns with …
Aethlon Medical, Inc. (NASDAQ:AEMD)announced its financial results for the fiscal second quarter ended September 30, 2025. Consolidatedoperating expensestotaled USD 1.5 Mn, down 48% from USD 2.9 Mn in Q2 2024. The decrease was primarily due to lower payroll, general and administrative, and professional expenses.
Molecular Partners AG (NASDAQ:MOLN), a clinical-stage biotech developing DARPin therapeutics, presented new data on MP0712, its lead Radio-DARPin targeting DLL3, at the Targeted Radiopharmaceuticals Summit Europe 2025. The presentation included first human images and supporting mechanism of action data, illustrating targeted tumor delivery. MP0712 …
DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, confirmed the completion of the last patient visit in its Phase 3 VITESSE trial. The study is evaluating the VIASKIN® Peanut patch in peanut-allergic children aged 4–7 years. This double-blind, placebo-controlled trial marks the end of the …
Please wait processing your request...